One of Akesobio's production workshops.

The 34th China Medicine Economic Information Conference (CMEIC) has been held recently, with the participation of more than 2,000 industry leaders and guests from over 500 pharmaceutical enterprises across China.

Due to its strong innovation strength and fruitful achievements in the biomedical field, Zhongshan-based company Akesobio claimed two awards: "Top Power - Enterprises with Remarkable Achievements in High-quality Development of China's Pharmaceuticals (2022)" and "Top Power - Brands with Remarkable Achievements in High-quality Development of China's Pharmaceuticals (2022)" for its self-developed Cadonilimab® (Cadonilimab Injection), the world's first PD-1/CTLA-4 bi-specific antibody drug approved for marketing.

So far, Akesobio has successfully developed more than 30 innovative drug candidates for oncology, autoimmunity, inflammation, metabolic disease and other major diseases, among which 17 novel drugs are under clinical research.